Nabumetone: a single-center three-week comparison with placebo in the treatment of rheumatoid arthritis.

Forty-six patients with definite or classical rheumatoid arthritis were entered into a three-week, double-blind, randomized, parallel study of nabumetone, 1,000 mg at bedtime, compared with placebo. Fifteen nabumetone-treated and 12 placebo-treated patients were evaluated for efficacy variables including physician's opinion of rheumatoid arthritis activity, patient's opinion of rheumatoid arthritis activity, articular index, morning stiffness, 50-foot walking time, grip strength, and acetaminophen consumption. Between-group analysis of improvement over baseline was significantly (p less than 0.05) greater for nabumetone-treated patients for six of the seven variables. Nabumetone was significantly favored over placebo in three global evaluations and significantly more placebo-treated (75 percent) than nabumetone-treated (20 percent) patients withdrew from the study due to an unsatisfactory therapeutic response. Of the 38 patients receiving the study medication, 22 percent of nabumetone-treated and 5 percent of placebo-treated patients reported adverse experiences either related to treatment or for which the relationship to treatment was unknown. No patients were withdrawn from the study as a result of these experiences and no long-term sequelae or clinically significant laboratory abnormalities were reported.
AuthorsR A Turner Jr, D A Brindley, F N Mitchell
JournalThe American journal of medicine (Am J Med) Vol. 83 Issue 4B Pg. 36-9 (Oct 30 1987) ISSN: 0002-9343 [Print] UNITED STATES
PMID3318426 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Butanones
  • Placebos
  • nabumetone
  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal (adverse effects, therapeutic use)
  • Arthritis, Rheumatoid (drug therapy)
  • Butanones (adverse effects, therapeutic use)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Middle Aged
  • Placebos
  • Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: